purple-logo2020.png
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
April 25, 2024 07:00 ET | Purple Biotech Ltd.
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) --...
purple-logo2020.png
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
March 28, 2024 07:00 ET | Purple Biotech Ltd.
NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in...
Arbutus Biopharma Logo
Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 05, 2022 07:30 ET | Arbutus Biopharma Corporation
Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Well positioned financially with a projected cash runway into the second quarter of 2024 ...
LOGO.png
Draganfly to Complete Listing of its Common Shares on Nasdaq Under the Symbol “DPRO”
July 22, 2021 09:00 ET | Draganfly Inc
Los Angeles, CA, July 22, 2021 (GLOBE NEWSWIRE) -- Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly”), a drone manufacturer and systems developer, announced today that it expects to...
Arbutus Biopharma Logo
Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent
July 07, 2021 07:00 ET | Arbutus Biopharma Corporation
Phase 2a trial to investigate the safety and anti-viral activity of AB-729 in combination with ongoing nucleos(t)ide analog (NA) therapy and short courses of Peg-IFNα-2a in subjects with chronic...
Arbutus Biopharma Logo
Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection
July 06, 2021 07:00 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa. and OXFORD, United Kingdom, July 06, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) and Vaccitech plc (Nasdaq: VACC) today announced that the companies have...
Arbutus Biopharma Logo
Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 05, 2021 07:30 ET | Arbutus Biopharma Corporation
AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B...
Arbutus Biopharma Logo
Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update
March 04, 2021 07:30 ET | Arbutus Biopharma Corporation
AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, demonstrates robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with...
Arbutus Biopharma Logo
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy SOUTH SAN FRANCISCO, Calif., and WARMINSTER,...
Arbutus Biopharma Logo
Arbutus Announces 2021 Corporate Objectives and Provides Financial Update
January 25, 2021 07:30 ET | Arbutus Biopharma Corporation
2021 objectives leverage positive momentum in Arbutus’ Hepatitis B research and development programs WARMINSTER, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS),...